Authors: Vogel, C Cobleigh, MA Tripathy, D Gutheil, JC Harris, LN Fehrenbacher, L Slamon, DJ Murphy, M Novotny, WF Burchmore, M Shak, S Stewart, SJ

Citation: C. Vogel et al., First-line, single-agent Herceptin (R) (trastuzumab) in metastatic breast cancer: a preliminary report, EUR J CANC, 37, 2001, pp. S25-S29

Authors: Vogel, CL Cobleigh, MA Tripathy, D Gutheil, JC Harris, LN Fehrenbacher, L Slamon, DJ Murphy, M Novotny, WF Burchmore, M Shak, S Stewart, SJ

Citation: Cl. Vogel et al., First-line Herceptin (R) monotherapy in metastatic breast cancer, ONCOL-BASEL, 61, 2001, pp. 37-42

Authors: Cobleigh, MA Vogel, CL Tripathy, D Robert, NJ Scholl, S Fehrenbacher, L Wolter, JM Paton, V Shak, S Lieberman, G Slamon, DJ

Citation: Ma. Cobleigh et al., Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease, J CL ONCOL, 17(9), 1999, pp. 2639-2648

Authors: Cobleigh, MA Norlock, FE Oleske, DM Starr, A

Citation: Ma. Cobleigh et al., Hormone replacement therapy and high S phase in breast cancer, J AM MED A, 281(16), 1999, pp. 1528-1530